Serum Thymidine Kinase 1 Activity in Solid Tumor (Breast and Colorectal Cancer) Patients Treated With Adjuvant Chemotherapy

The aim of this study was to evaluate the changing of TK1 (where TK is thymidine kinase) activity before and after adjuvant chemotherapy in patients with breast and colorectal cancer.

[1]  S. Eriksson,et al.  A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma. , 2012, Veterinary journal.

[2]  J. Boder,et al.  Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer , 2012, Tumor Biology.

[3]  L. Kadouri,et al.  Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients , 2012, Clinical chemistry and laboratory medicine.

[4]  Shung-Haur Yang,et al.  Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis , 2012, International Journal of Colorectal Disease.

[5]  Xingsong Tian,et al.  Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. , 2012, Experimental and Therapeutic Medicine.

[6]  K. Tatsch,et al.  Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy , 2012, BMC Cancer.

[7]  Yan Chen,et al.  Serological Thymidine Kinase 1 is a Biomarker for Early Detection of Tumours—A Health Screening Study on 35,365 People, Using a Sensitive Chemiluminescent Dot Blot Assay , 2011, Sensors.

[8]  Y. Ling,et al.  Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. , 2011, Experimental and therapeutic medicine.

[9]  S. Oh,et al.  Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare. , 2010, Biochemical pharmacology.

[10]  Y. Li,et al.  Thymidine Kinase 1 is a Potential Marker for Prognosis and Monitoring the Response to Treatment of Patients with Breast, Lung, and Esophageal Cancer and Non-Hodgkin's Lymphoma , 2010, Nucleosides, nucleotides & nucleic acids.

[11]  Xia Yun,et al.  Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings , 2010, International Journal of Clinical Oncology.

[12]  Jie Ma,et al.  Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma. , 2010, Anticancer research.

[13]  Xing-Ying Ji,et al.  Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients , 2010, Journal of Cancer Research and Clinical Oncology.

[14]  Staffan Eriksson,et al.  Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker , 2009, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[15]  Ellen He,et al.  Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. , 2008, Molecular medicine reports.

[16]  Ondrej Topolcan,et al.  The role of thymidine kinase in cancer diseases. , 2008, Expert opinion on medical diagnostics.

[17]  O. Topolcan,et al.  Prognostic importance of thymidine kinase in colorectal and breast cancer. , 2007, Anticancer research.

[18]  J. Byrd,et al.  Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia , 2006, Current opinion in hematology.

[19]  M. Duffy,et al.  Serum tumor markers in breast cancer: are they of clinical value? , 2006, Clinical chemistry.

[20]  Wei Zhang,et al.  Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. , 2006, Oncology reports.

[21]  Xiuqin Wang,et al.  Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. , 2005, Oncology reports.

[22]  R. Lamerz,et al.  Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. , 2005, Anticancer research.

[23]  R. Einarsson,et al.  Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. , 2004, Journal of veterinary internal medicine.

[24]  L Zou,et al.  The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. , 2002, The International journal of biological markers.

[25]  B. K. Murray,et al.  Thymidine kinase: diagnostic and prognostic potential , 2001, Expert review of molecular diagnostics.

[26]  B Asselain,et al.  Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Foekens,et al.  Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. , 2001, Cancer research.

[28]  M. Duffy,et al.  CA 15–3: A Prognostic Marker in Breast Cancer , 2000, The International journal of biological markers.

[29]  B. Emmerich,et al.  Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications , 1992, Annals of Hematology.

[30]  B Simonsson,et al.  Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia , 1984, Cancer.

[31]  A. Kastania,et al.  Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics. , 2012, Clinical laboratory.

[32]  T. Peretz,et al.  Serum thymidine kinase 1 activity in breast cancer. , 2010, Cancer biomarkers : section A of Disease markers.

[33]  Anders Larsson,et al.  Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer , 2009, Upsala journal of medical sciences.